Cargando…

Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study

PURPOSE: To investigate postoperative mortality rates and risk factors for mortality after surgical treatment of benign prostate hyperplasia (BPH). METHODS: All patients who underwent partial prostate excision/resection from 2004 to 2014 in Finland were retrospectively assessed for eligibility using...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmivalli, Alisa, Ettala, Otto, Boström, Peter J., Kytö, Ville
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236974/
https://www.ncbi.nlm.nih.gov/pubmed/35429257
http://dx.doi.org/10.1007/s00345-022-03999-0
_version_ 1784736660181745664
author Salmivalli, Alisa
Ettala, Otto
Boström, Peter J.
Kytö, Ville
author_facet Salmivalli, Alisa
Ettala, Otto
Boström, Peter J.
Kytö, Ville
author_sort Salmivalli, Alisa
collection PubMed
description PURPOSE: To investigate postoperative mortality rates and risk factors for mortality after surgical treatment of benign prostate hyperplasia (BPH). METHODS: All patients who underwent partial prostate excision/resection from 2004 to 2014 in Finland were retrospectively assessed for eligibility using a nationwide registry. Procedures were classified as transurethral resection of the prostate (TURP), laser vaporization of the prostate (laser), and open prostatectomy. Univariable and multivariable regression were used to analyze the association of age, Charlson comorbidity index (CCI), operation type, annual center operation volume, study era, atrial fibrillation, and prostate cancer diagnosis with 90 days postoperative mortality. RESULTS: Among the 39,320 patients, TURP was the most common operation type for lower urinary tract symptoms in all age groups. The overall 90 days postoperative mortality was 1.10%. Excess mortality in the 90 days postoperative period was less than 0.5% in all age groups. Postoperative mortality after laser operations was 0.59% and 1.16% after TURP (p = 0.035). Older age, CCI score, and atrial fibrillation were identified as risk factors for postoperative mortality. Prostate cancer diagnosis and the center’s annual operation volume were not significantly associated with mortality. The most common underlying causes of death were malignancy (35.5%) and cardiac disease (30.9%). CONCLUSION: Elective urologic procedures for BPH are generally considered safe, but mortality increases with age. Laser operations may be associated with lower mortality rates than the gold standard TURP. Thus, operative risks and benefits must be carefully considered on a case-by-case basis. Further studies comparing operation types are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-03999-0.
format Online
Article
Text
id pubmed-9236974
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92369742022-06-29 Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study Salmivalli, Alisa Ettala, Otto Boström, Peter J. Kytö, Ville World J Urol Original Article PURPOSE: To investigate postoperative mortality rates and risk factors for mortality after surgical treatment of benign prostate hyperplasia (BPH). METHODS: All patients who underwent partial prostate excision/resection from 2004 to 2014 in Finland were retrospectively assessed for eligibility using a nationwide registry. Procedures were classified as transurethral resection of the prostate (TURP), laser vaporization of the prostate (laser), and open prostatectomy. Univariable and multivariable regression were used to analyze the association of age, Charlson comorbidity index (CCI), operation type, annual center operation volume, study era, atrial fibrillation, and prostate cancer diagnosis with 90 days postoperative mortality. RESULTS: Among the 39,320 patients, TURP was the most common operation type for lower urinary tract symptoms in all age groups. The overall 90 days postoperative mortality was 1.10%. Excess mortality in the 90 days postoperative period was less than 0.5% in all age groups. Postoperative mortality after laser operations was 0.59% and 1.16% after TURP (p = 0.035). Older age, CCI score, and atrial fibrillation were identified as risk factors for postoperative mortality. Prostate cancer diagnosis and the center’s annual operation volume were not significantly associated with mortality. The most common underlying causes of death were malignancy (35.5%) and cardiac disease (30.9%). CONCLUSION: Elective urologic procedures for BPH are generally considered safe, but mortality increases with age. Laser operations may be associated with lower mortality rates than the gold standard TURP. Thus, operative risks and benefits must be carefully considered on a case-by-case basis. Further studies comparing operation types are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-03999-0. Springer Berlin Heidelberg 2022-04-16 2022 /pmc/articles/PMC9236974/ /pubmed/35429257 http://dx.doi.org/10.1007/s00345-022-03999-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Salmivalli, Alisa
Ettala, Otto
Boström, Peter J.
Kytö, Ville
Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
title Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
title_full Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
title_fullStr Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
title_full_unstemmed Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
title_short Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
title_sort mortality after surgery for benign prostate hyperplasia: a nationwide cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236974/
https://www.ncbi.nlm.nih.gov/pubmed/35429257
http://dx.doi.org/10.1007/s00345-022-03999-0
work_keys_str_mv AT salmivallialisa mortalityaftersurgeryforbenignprostatehyperplasiaanationwidecohortstudy
AT ettalaotto mortalityaftersurgeryforbenignprostatehyperplasiaanationwidecohortstudy
AT bostrompeterj mortalityaftersurgeryforbenignprostatehyperplasiaanationwidecohortstudy
AT kytoville mortalityaftersurgeryforbenignprostatehyperplasiaanationwidecohortstudy